CAS: 170572-49-3; 3-Fluoro-4-Methylbenzonitrile

相似化合物

350-28-7 177756-62-6 170572-50-6

上下游产品

CAS号59189-97-8 3-氟-4-甲基苯甲酰氯 | CAS号51436-99-8 4-溴-2-氟甲苯 | CAS号104-85-8 对甲苯腈 | CAS号121-44-8 三乙胺 | CAS号76-02-8 三氯乙酰氯 | CAS号170726-98-4 3-Fluoro-4-meth... | CAS号544-92-3 氰化亚铜 | CAS号350-28-7 3-氟-4-甲基苯甲酸 | CAS号177756-62-6 3-氟-4-甲基苯甲醛 | CAS号192702-79-7 3-氟-4-甲基苯甲醇 | CAS号105942-09-4 4-(溴甲基)-3-氟苯腈 | CAS号1146699-62-8 4-二溴甲基-3-氟苯甲腈 | CAS号329744-58-3 4-(diethoxyphos... | CAS号329744-59-4 3-fluoro-4-(5-o... | CAS号105942-10-7 4-氰基-2-氟苯甲醛 | CAS号170726-99-5 3-fluoro-4-(hyd... | CAS号164149-28-4 4-氰基-2-氟苯酸 | CAS号238742-80-8 3-氟-4-甲基苯甲酰胺肟 | CAS号928134-65-0 Osilodrostat (L...

3-氟-4-甲基苯甲酰氯置于三乙胺,三氯乙酰氯体系中,用 二氯甲烷 用作溶剂,化学反应 1.0H,以100%的收率获得3-氟-4-甲基苯腈
参考文献:发现了一系列口服活性的异恶唑啉糖蛋白iib / Iiia拮抗剂.
标题:发现了一系列口服活性的异恶唑啉糖蛋白iib / Iiia拮抗剂.
摘要:使用异恶唑啉xr299(1A)作为设计高效,长效gpiib / Iiia拮抗剂的起点,评估了将亲脂性取代基置于羧酸酯部分的α和β处的效果.在所研究的化合物中,发现氨基甲酸正丁酯24U在狗中表现出优异的效力和离体抗血小板作用的持续时间.用可替代的碱性基团取代苯并胺丁-4-基部分,消除异恶唑啉立体中心,并改变异恶唑啉环的方向,导致效力和/或作用时间降低.
Doi:10.1021/jm960799I

专利信息

专利号:US-8772301-B2
优先权日:2009-12-18
标题 :Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
发明人：HARDY LARRY WENDELL; HEFFERNAN MICHELE L R; WU FRANK XINHE; SPEAR KERRY L; SARASWAT LAKSHMI D
权利人:HARDY LARRY WENDELL; HEFFERNAN MICHELE L R; WU FRANK XINHE; SPEAR KERRY L; SARASWAT LAKSHMI D; SUNOVION PHARMACEUTICALS INC
摘要:Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

专利号:US-2008269233-A1
优先权日:2005-08-04
标 题:Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds
发明人：ANDREWS MARK DAVID; BROWN ALAN DANIEL; SEBASTIEN DAVID; LANSDELL MARK IAN
权利人:ANDREWS MARK DAVID; BROWN ALAN DANIEL; SEBASTIEN DAVID; LANSDELL MARK IAN
摘要:The present invention relates to a class of compounds of general formula (I) n n n n n n n n n n and the salts, hydrates, solvates, polymorphs and prodrugs wherein n, R 6 , R 7 and R 10 are as defined herein and especially to MCR4 agonist compounds of formula (I), to their use in medicine, particularly in the treatment of sexual dysfunction and obesity, to intermediates useful in their synthesis and to compositions containing them.

专利号:EP-1641453-B1
优先权日:2003-06-25
标题 :Product containing at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent
发明人：PREVOST GREGOIRE; BREZAK PANNETIER MARIE-CHRISTINE; DIOLEZ CHRISTIAN
权利人:IPSEN PHARMA
摘要:The invention relates to a product containing at least one phosphatase Cdc25 inhibitor combined with at least one other anticancer agent for simultaneous, separate or staggered therapeutic use during treatment for cancer. According to the invention, the other anticancer agent is preferably selected from: DNA base analogs such as 5-fluorouracil; inhibitors of type I and/or type II topoisomerases, such as camptothecin and the analogs thereof, doxorubicin or amsacrine; compounds interacting with the cellular spindle, for example, paclitaxel (Taxol); compounds acting on the cytoskeleton, such as vinblastine; inhibitors of the transduction of the signal passing via the heterotrimeric G proteins; prenyltransferase inhibitors, and especially farnesyltransferase inhibitors; cyclin-dependent kinase (CDKs) inhibitors; alkylating agents such as cisplatin; folic acid antagonists such as methotrexate; and inhibitors of DNA synthesis and cellular division, such as mitomycin C. The invention also relates to (1R)-1-[({(2R)-2-amino--3-[(8S)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]--3-oxopropyl}dithio)methyl]-2-[(8S)-8-(cyclohexylmethyl)-2-phenyl--5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]-2-oxoethylamine, or the pharmaceutically acceptable salts thereof, that can be used as anticancer agents.